Editorial
Stereotactic body radiotherapy for early-stage non-small cell lung cancer: a surgical perspective on the American Society for Radiation Oncology Guidelines
Abstract
Stereotactic body radiation therapy (SBRT) has emerged as a safe and effective treatment modality for selected patients with non-small cell lung cancer (NSCLC) (1). Compared with other radiation techniques, SBRT is delivered with fewer fractions of higher-dose radiation that are directed more precisely at located targets, providing a higher biologically effective dose while minimizing toxicity to the surrounding normal tissue.